Oncology Developer Yahong Bags China’s First Biotech IPO Of 2022

Active Funding Ahead Of Lunar New Year

 
• By Dexter Jie Yan

Jiangsu Yahong and 11 Chinese biotechs raised a combined $1.1bn via public listings and VC/PE deals in the run-up to and first week of the new year.

fund raising
VC/PE funds continued pumping fresh funds into Chinese biotechs despite sluggish performance of publicly traded companies • Source: Alamy

More from China

More from Focus On Asia